Critical appraisal:Leong RW, Ooi M, Corte C, Yau Y, Kermeen M, Katelaris PH, et al 2017 1
From Cancer Guidelines Wiki
Risk of bias assessment: Randomised Controlled Trial (Cochrane risk of bias tool)
Random sequence generation
Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.
- Computer-generated code
Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of or during, enrolment.
- Concealed in an opaque envelope and revealed after informed consent was obtained
Describe all measures used, if any, to blind outcome assessors from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.
- Gastrointestinal pathologists were blinded to the colonoscope allocation, but endoscopists were not blinded to the colonoscopy examinations.
Incomplete outcome data
Describe the completeness of outcome data for each main outcome, including attrition and exlusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition/exclusions where reported, and any re-inclusions in analyses performed by the review authors.
- Main outcome was dysplasia missed by the first colonoscopy. Both the primary outcome and secondary outcomes were reported.
Selective outcome reporting
State how the possibility of selective outcome reporting was examined by the review authors and what was found.
- All primary and secondary outcomes were reported
What was the risk of bias from selective outcome reporting? Assessments should be made for each main outcome (or class of outcomes).
Other sources of bias
Overall risk of bias
|Low risk of bias
|Additional comments: Please replace this text and include any additional comments in regards to your risk of bias rating
- Leong RW, Ooi M, Corte C, Yau Y, Kermeen M, Katelaris PH, et al. Full-Spectrum Endoscopy Improves Surveillance for Dysplasia in Patients With Inflammatory Bowel Diseases. Gastroenterology 2017 May;152(6):1337-1344.e3 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28126349.
- Assigned to
- Topic area
- Guidelines:Colorectal cancer/Colonoscopy surveillance
- Clinical question
- Form:Quality appraisal rct-cochrane
- Detection of dysplasia by FUSE vs Forward-viewing Colonoscopy +/- Chromoendoscopy
Section below only relevant for Cancer Council Project Officer